Valuation: Eupraxia Pharmaceuticals Inc.

Market Cap 631M 451M 403M 372M 337M 42.81B 641M 4.48B 1.77B 22.43B 1.69B 1.66B 70.71B P/E 2026 *
-6.76x
P/E 2027 * -6.65x
Enterprise Value 631M 451M 403M 372M 337M 42.81B 641M 4.48B 1.77B 22.43B 1.69B 1.66B 70.71B EV / Sales 2026 *
-
EV / Sales 2027 * 889x
Free-Float
87.89%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week-2.03%
Current month-25.87%
1 month-17.34%
3 months+10.18%
6 months-2.43%
Current year-6.69%
1 week 9.37
Extreme 9.37
11.08
1 month 9.2
Extreme 9.2
13.08
Current year 7.85
Extreme 7.85
13.08
1 year 7.35
Extreme 7.35
13.08
3 years 3.07
Extreme 3.07
13.08
5 years 0.8
Extreme 0.8
13.08
10 years 0.8
Extreme 0.8
13.08
Manager TitleAgeSince
Chief Executive Officer - 2012-07-22
Director of Finance/CFO - 2025-02-17
Chief Tech/Sci/R&D Officer - 2026-04-30
Director TitleAgeSince
Chairman 58 2013-01-13
Director/Board Member - 2012-07-22
Director/Board Member 61 2013-01-13
Date Insider Type Main position Quantity % Market Cap. Importance
9/23/26 Sell

Director

-387,300 0.5876%
9/23/26 Sell

Director

-1,200,000 1.8208%
9/23/26 Sell

Director

-1,215,280 1.8439%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-2.03%+27.21%+73.51% 451M
+2.41%+0.29%+39.41%+73.38% 64.69B
-0.10%+7.04%+9.94%+77.59% 54.78B
+0.32%+3.33%+9.51%+100.57% 53.49B
+0.57%+5.61%+29.15%+52.26% 45.98B
-1.27%+1.30%+18.89%+126.11% 42.94B
-2.66%+0.40%+215.35%+818.48% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+0.22%-8.29%+23.12%+3.15% 23.97B
+12.52%+17.70%+60.00%+47.53% 23.67B
Average +1.21%+2.41%+45.06%+142.11% 38.36B
Weighted average by Cap. +0.82%+2.73%+44.26%+150.84%

Financials

2026 *2027 *
Net sales - 710K 508K 453K 419K 379K 48.18M 722K 5.04M 1.99M 25.24M 1.9M 1.86M 79.58M
Net income -92.49M -66.13M -59.05M -54.55M -49.44M -6.28B -94.02M -656M -260M -3.29B -248M -243M -10.37B -104M -74.26M -66.31M -61.26M -55.52M -7.05B -106M -737M -292M -3.69B -279M -273M -11.64B
Net Debt - -
Projected Income Statement - Annual - Eupraxia Pharmaceuticals Inc.
Logo Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Employees
-
Date Price Change Volume
26-10-26 $9.630 +0.63% 5,077
26-10-23 $9.570 -10.14% 82,131
26-10-22 $10.65 -1.39% 135,893
26-10-21 $10.80 +0.75% 115,555
26-10-20 $10.72 +9.05% 175,805
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Eupraxia Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
9.570CAD
Average target price
16.33CAD
Spread / Average Target
+70.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eupraxia Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. EPRX Stock